Thank you for donating!

You can donate using the following services.

News

  1. 27.04.21

    Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

    Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from diseases, today announced that it has posted its protocol on www.ClinicalTrials.gov and is preparing to commence its pivotal Phase 3 study evaluating Trappsol® Cyclo™...

    Read more
  2. 15.04.21

    Tony Jellings: Former NPUK Trustee & Fundraising Coordinator

    As we celebrate our milestone 30th year as a small charity, we are pleased to be joined by another instrumental former member of the Niemann-Pick UK Board of Trustees, Tony Jellings. Tony has kindly provided us with the following article which provides more detail surrounding his family's connection with Niemann-Pick disease, and his fantastic support throughout the years that followed...

    Read more
  3. 14.04.21

    Cyclo Therapeutics Inc: Update (13/4/21)

    Read more
  4. 25.03.21

    Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)

    Read more
  5. 16.03.21

    University College London begins preclinical studies to develop a treatment for Niemann Pick C disease with support from the Columbus Foundation

    Read more